[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sociedad Española de Neumología y Cirugía Torácica\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100358538","normotensive-osa-patients-with-dipper-circadian-blood-pressure-pattern-100358538",false,"NCT03948373","Normotensive OSA Patients With Dipper Circadian Blood Pressure Pattern","CPAP Effect in Nocturnal Blood Pressure in Normotensive Patients With Dipper Circadian Pattern and Severe Obstructive Sleep Apnea (OSA)","Inclusion Criteria:\n\n1. Men and women over 18 years of age\n2. Referred to the sleep unit for suspected OSA\n3. Being normotensive and presenting an AHI ≥ 30 in the sleep study\n4. Signature of the informed consent.\n\nExclusion Criteria:\n\n1. Previous CPAP treatment\n2. Significant somnolence defined by an Epworth Sleepiness Scale (ESS) score higher than 18\n3. Psychophysical inability to complete questionnaires\n4. Previous diagnosis or suspicion of another sleep disorder\n5. Presence of more than 50% of central apneas or Cheyne-Stokes respiration\n6. Having a serious chronic disease: neoplasia, renal failure, severe chronic obstructive pulmonary disease, chronic depression and other chronic limiting diseases\n7. Medical history that may interfere with the objectives of the study or, in the opinion of the researcher, may compromise the conclusions\n8. Any medical, social or geographical factor that may endanger the patient's compliance 9-Having a profession of high risk (professional driver).","ALL","18 Years","100 Years",{"count":20,"type":21},64,"ESTIMATED","INTERVENTIONAL",[24],"NA","The principal objective is to evaluate the effect of CPAP treatment on blood pressure (BP) in normotensive patients with dipper circadian pattern with sleep apnea-hypopnea syndrome (SAHS). The secondary objectives are: i) To evaluate the prevalence of the different circadian patterns of BP in ambulatory blood pressure monitoring (ABPM) ii) To establish the relationship between CPAP compliance and BP response; iii) Identify which ABPM variables and biomarkers are related to BP response; iv) Evaluate changes in the biomarkers' profile with the CPAP treatment. Methodology: Open-label, parallel, prospective, randomized and controlled trial including normotensive patients diagnosed with severe SAHS without significant somnolence. 64 patients with dipper circadian pattern will be included and will be randomized to receive CPAP (32) or conservative treatment (32). ABPM and blood sample collection will be performed at the beginning of the study and at 3 months.",[27,28],"Normotensive","Sleep Apnea, Obstructive","RECRUITING","2025-02-25",{"date":32,"type":33},"2025-02-26","ACTUAL",{"date":35,"type":33},"2019-05-07",{"date":37,"type":21},"2025-12",{"name":39,"class":40},"Sociedad Española de Neumología y Cirugía Torácica","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":41},"100515052","impact-of-sleep-disordered-breathing-management-in-systemic-hypertension-control-metasleep-project-100515052","NCT05986487","Impact of Sleep-Disordered Breathing Management in Systemic Hypertension Control: METASLEEP Project","Inclusion Criteria:\n\n* Patients with arterial hypertension who visit their primary care physician in one of the participating primary care centers.\n* Signature of the informed consent.\n\nExclusion Criteria:\n\n* Psycho-physical inability to complete questionnaires.\n* Patients with very limiting chronic disease.\n* Previous diagnosis of OSA or any other sleeping disorder\n* Active treatment with CPAP.\n* Fixed night shift worker.",{"count":49,"type":21},1523,"OBSERVATIONAL","Hypertension is a frequent condition affecting 11M Spanish citizens and is the leading modifiable contributor to cardiovascular disease and death. Our society has already identified balanced diet, physical activity and emotional wellbeing as the 3 pillars of healthy living. Healthy sleep should be incorporated as the fourth pillar, as clearly supported by the extensively available scientific evidence. Targeting sleep is considered the new frontier in cardiovascular prevention. In fact, recent scientific evidence encourages consideration of including sleep disturbances in the top 10 potentially modifiable cardiovascular risk factors. Sleep-disordered breathing affect 30-80% of patients with hypertension. The personalized management of hypertension is challenging due to; i) the misclassification of hypertensive patients (affecting 1 out of 3 patients); ii) the lack of adequate treatment of high mortality risk hypertensive phenotypes today is an unmet clinical need; iii) unawareness of the impact of sleep-disordered breathing as a modifiable risk factor for hypertension. Importantly, the investigators already made the seminal observations showing that the treatment for sleep-disordered breathing reduces blood pressure in the hypertensive phenotypes with the highest mortality risk. Given the need for novel strategies to treat hypertension and, supported by our data, the investigators propose to study and treat sleep-disordered breathing to improve hypertension control. METASLEEP will go beyond current state-of the-art providing a new paradigm for the accurate hypertension classification and treatment. This project will open up a new avenue on the therapeutic potential of the management of sleep-disordered breathing in hypertension.",[53,54],"Hypertension","Obstructive Sleep Apnea","2024-11-27",{"date":57,"type":33},"2024-12-03",{"date":59,"type":33},"2024-04-16",{"date":37,"type":21},{"name":39,"class":40},""]